Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 25 (TRAJ25)
- Target
- TRAJ25
- Molecular classification
- Other (genomic segment; pseudogene)
01
Overview
T cell receptor alpha joining 25 (TRAJ25) is a genomic segment located on chromosome 14 that encodes a joining region of the TCRα chain required for V-J recombination during T cell receptor assembly. However, TRAJ25 is annotated as non-functional and is considered a pseudogene, meaning it does not encode a usable J segment in the context of protein function or therapeutic targeting. The joining (J) segments are critical for the diversity of antigen recognition, but pseudogenes like TRAJ25 do not contribute functional protein products. Therefore, TRAJ25 is not an actionable therapeutic target nor a biomarker, and does not interact with drugs or play a role in disease pathology.
- Other names
- TRAJ25 (HGNC symbol)T cell receptor alpha joining 25
02
Mechanism of action
Not applicable for TRAJ25; mechanisms for drugs against TCRs generally include inhibition/activation of T cell signaling
03
Biological functions
None for TRAJ25 individually (it is annotated as non-functional and does not encode a protein)In a broader sense, functional TRAJ segments participate in the generation of the TCRα variable region, thus supporting antigen recognition in functional context
04
Disease associations
None known for TRAJ25 specifically; defects or variations involving other TCRα components may affect immune function
05
Safety considerations
None for TRAJ25 itself; general safety concerns exist for drugs targeting T cell receptors (e.g., immune suppression, cytokine release syndrome)
06
Interacting drugs
None for TRAJ25; drugs may target TCR complex in general (e.g., immunomodulators, antibodies), but not this J segment
07
Biomarkers
None for TRAJ25 specifically; some TCR rearrangement patterns are studied as biomarkers in hemato-lymphoid diseases, but not this pseudogene
Beyond the preview
Go deeper on T cell receptor alpha joining 25 (TRAJ25).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T cell receptor alpha joining 25 (TRAJ25).